[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350270-105":59,"doc-detail-350270-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","bevacizumab-irdye800-as-an-imaging-probe-for-the-detection-of-prostate-cancer-in-mice","Bevacizumab-IRDye800 as an imaging probe for the detection of prostate cancer in mice","","VEGF-A signaling is central to carcinogenesis, prompting evaluation of a fluorescently labeled monoclonal antibody as a prostate-cancer probe. Bioluminescent human PC3 cells were implanted orthotopically to establish prostate tumors in mice. Bevacizumab was conjugated to a near-infrared fluorophore, producing Bevacizumab-IRDye800, injected intravenously for in vivo monitoring by fluorescence molecular tomography. After 72 hours, fluorescence localized to the prostate region and overlaid with bioluminescent tumor signal on excised organs, supporting high-affinity contrast performance and enabling broader detection of solid cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bevacizumab-irdye800-as-an-imaging-probe-for-the-detection-of-prostate-cancer-in-mice/350270/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bevacizumab-irdye800-as-an-imaging-probe-for-the-detection-of-prostate-cancer-in-mice/350270.png","ImageObject",300,407,{"name":92,"@type":93},"Putri","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was prostate cancer modeled for the probe evaluation?","Question",{"text":112,"@type":113},"Orthotopic prostate tumors were generated by injecting bioluminescent human PC3 cells into the prostate lobe, enabling bioluminescence readout in vivo.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is Bevacizumab-IRDye800 and how was it used?",{"text":117,"@type":113},"Bevacizumab was labeled with a near-infrared fluorophore to create Bevacizumab-IRDye800, which was injected intravenously into tumor-bearing mice for fluorescence monitoring.",{"name":119,"@type":110,"acceptedAnswer":120},"What imaging method detected Bevacizumab-IRDye800 in vivo?",{"text":121,"@type":113},"Fluorescence molecular tomography (FMT) was used to detect Bevacizumab-IRDye800 signal in the prostate region 72 hours after injection.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350270,1790934858,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nBevacizumab-IRDye800 as an imaging probe for the detection of prostate cancer in mice  \nCoralie Genevois1,2, Nathalie Dugot-Senant3, Marie-Helene Canron4, Lamia Azzi-Martin1, Nicolas Grenier1,5, Franck Couillaud1 & Claire Mazzocco4􀀍  \nVascular endothelial growth factor (VEGF) signalling plays a critical role in carcinogenesis and tumour development in several types of cancer. Therefore, we sought to evaluate a fluorescently labelled monoclonal antibody against VEGF-A (Bevacizumab) as a probe for the detection of prostate cancer by in vivo fluorescence imaging. An orthotopic model of prostate cancer was generated by injecting bioluminescent human PC3 cells into the prostate lobe, followed by bioluminescence in vivo. Bevacizumab was labelled using a near-infrared fluorophore to generate a specific imaging probe (Bevacizumab-IRDye800). The probe was injected intravenously into prostate cancer-bearing mice, and fluorescence was monitored in vivo by fluorescence molecular tomography (FMT). 72 h post-injection, Bevacizumab-IRDye800 was detected in vivo by FMT in the prostate region. On excised prostates, the fluorescence signal overlaid with the bioluminescent signal from cancer cells. Our data demonstrate that Bevacizumab-IRDye800 is a high-affinity contrast agent for in vivo detection of prostate cancer tumours, paving the way to further development of near-infrared-labelled Bevacizumab-IRDye800 for the detection of other solid cancers.  \nKeywords Prostate cancer, In vivo imaging, Fluorescent molecular tomography, Monoclonal antibody, Bevacizumab, Metastases  \nProstate cancer (PCa) is the second most frequently diagnosed malignancy and ranks as the fifth leading cause of cancer-related mortality among men, with increasing incidence with age1. In many cases, the disease is diagnosed at an advanced stage, which is a risk of metastasis and mortality2. The initial diagnosis of prostate cancer is made by measuring serum Prostate Specific Antigen (PSA) levels and performing a digital rectal examination3, but the gold standard for confirming the diagnosis is defined by histopathological evaluation of prostate biopsy specimens using the Gleason grading system4,5.  \nOne of the promising molecular targets for PCa detection6 is currently the prostate-specific membrane antigen (PSMA), a prominent prostate cancer marker due to its over-expression in all stages ofthe disease, from primary to metastasis6,7. PSMA has long been recognised as a valuable diagnostic target in prostate cancer imaging. Oneof the earliest agents, ProstaScint® (capromab pendetide), is a radiolabelled murine monoclonal antibody (7E11) approved for scintigraphy. However, 7E11 binds to an intracellular epitope ofPSMA, which becomes accessible only in damaged or necrotic cells8,9. As a result, its utility is limited when it comes to detecting viable tumour tissue.  \nTo address this, more recent anti-PSMA antibodies such as J591 have been designed to target extracellular epitopes, allowing better visualisation of living tumour cells. These antibodies have shown improved performance in both imaging and therapeutic applications, including PET-based diagnostics and targeted radionuclide therapy. In addition to antibodies, several small molecules have been described as ligands to the extracellular domain of PSMA, such as DCFBC or HBED-CC1710, 11. Using these ligands with 68Gallium-or 18 F-labelled, there has been a rapid development of PSMA-PET in metastatic or recurrent prostate cancer imaging12. Recently, PET/MRI technology was demonstrated to offer better detection of prostate cancer13, but its low availability, its high cost, and the use of radioactive markers preclude its use in large detection strategies and primary biopsy guidance, and have opened the field for cold tracers.  \n1BoRdeaux Institute of onCology (BRIC), INSERM U1312, Univ. Bordeaux, 146 rue Léo Saignat, Bordeaux 33076, France. 2Viv","cbCaiizxmJ4AddDy","https://ap.wps.com/l/cbCaiizxmJ4AddDy","pdf",2499553,11,"English","# Bevacizumab-IRDye800 probe evaluation\n## In vivo prostate cancer model and probe preparation\n## Fluorescence molecular tomography imaging results\n## Background: VEGF-A and prostate cancer detection targets\n## Comparison with PSMA-based imaging approaches","[{\"question\":\"How was prostate cancer modeled for the probe evaluation?\",\"answer\":\"Orthotopic prostate tumors were generated by injecting bioluminescent human PC3 cells into the prostate lobe, enabling bioluminescence readout in vivo.\"},{\"question\":\"What is Bevacizumab-IRDye800 and how was it used?\",\"answer\":\"Bevacizumab was labeled with a near-infrared fluorophore to create Bevacizumab-IRDye800, which was injected intravenously into tumor-bearing mice for fluorescence monitoring.\"},{\"question\":\"What imaging method detected Bevacizumab-IRDye800 in vivo?\",\"answer\":\"Fluorescence molecular tomography (FMT) was used to detect Bevacizumab-IRDye800 signal in the prostate region 72 hours after injection.\"}]","Bevacizumab-IRDye800 as an imaging probe for the detection of prostate cancer in mice | PDF",1790088183,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0623204ca4cbce636a9673b2527d7256.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d66fa5516b2d47fd48044148c0d248b0.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80f50c26199146dfb46ff303eafd71a7.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb7804bddc54881dc8885bb0ad5fcd6a.webp",980,1287]